Cerus Corp (NASDAQ:CERS)
| Market Cap | $373.61M+14.2% |
| Revenue (ttm) | $226.57M+13.7% |
| Net Income | -$7.31M+54.2% |
| EPS | -$0.04+54.2% |
| Shares Out | 201.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,512,960 |
| Open | $1.84 |
| Previous Close | $1.90 |
| Day's Range | $1.82 - $1.95 |
| 52-Week Range | $1.59 - $3.47 |
| Beta | 1.85 |
| Analysts | Buy |
| Price Target | $4.00(+116.22%) |
| Earnings Date | Mar 1, 2027 |
About CERS
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 1, 2027Earnings report
$CERS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CERS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CERS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CERS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CERS Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CERS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CERS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CERS
| ARKKARK Innovation ETF | $31.00M |
| ARKGARK Genomic Revolution ETF | $15.79M |
| VTIVanguard Morningstar Total Stock Market ETF | $10.92M |
| IWMiShares Russell 2000 ETF | $9.93M |
| VXFVanguard Extended Market ETF | $5.12M |
| IWOiShares Russell 2000 Growth ETF | $3.63M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CERS’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| ARKG | ARK Genomic Revolution ETF | 0.85% |
| XHE | State Street SPDR S&P Health Care Equipment ETF | 0.74% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.45% |
| FSML | Franklin Small Cap Enhanced ETF | 0.40% |
| ARKK | ARK Innovation ETF | 0.30% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.13% |
| FVI | First Trust Total US Market AlphaDEX ETF | 0.11% |
| IWC | iShares Micro-Cap ETF | 0.10% |
| GSSC | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | 0.06% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.06% |
| SMLF | iShares U.S. Small-Cap Equity Factor ETF | 0.05% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
